2002•PubMedRequires access

[Antithrombotic drugs in atrial fibrillation].

Françoise Hidden‐Lucet

Open publisher page 0 citations

Abstract

Stroke and peripheral thrombo-embolism are common in all forms of atrial fibrillation which is responsible for a hypercoagulable state. Clinical and echocardiographic risk stratification allow therapeutic recommendations among the different antithrombotic strategies used in randomized studies (adjusted-dose oral anticoagulant, aspirin or a combination of aspirin and low-dose oral anticoagulant) in agreement with recent guidelines from the European and American associations of cardiology for the managMent of patients with atrial fibrillation.

About this research paper

What this paper is about

Stroke and peripheral thrombo-embolism are common in all forms of atrial fibrillation which is responsible for a hypercoagulable state. Clinical and echocardiographic risk stratification allow therapeutic recommendations among the different antithrombotic strategies used in randomized studies (adjusted-dose oral anticoagulant, aspirin or a combination of aspirin and low-dose oral anticoagulant) in agreement with recent guidelines from the European and American associations of cardiology for the managMent of patients with atrial fibrillation.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Stroke and peripheral thrombo-embolism are common in all forms of atrial fibrillation which is responsible for a hypercoagulable state. Clinical and echocardiographic risk stratification allow therapeutic recommendations among the different antithrombotic strategies used in randomized studies (adjusted-dose oral anticoagulant, aspirin or a combination of aspirin and low-dose oral anticoagulant) in agreement with recent guidelines from the European and American associations of cardiology for the managMent of patients with atrial fibrillation.

Key concepts: Medicine, Antithrombotic, Atrial fibrillation, Aspirin, Cardiology, Risk stratification, Anticoagulant, Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
[Antithrombotic drugs in atrial fibrillation]. — Research Paper | ScholarLens